Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01005 vs Zoladex in Prostate Cancer
NCT04563936Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Baituowei in prostate cancer (PCa) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Percentage of subjects with serum testosterone <= 50 ng/dL on Day 29 and Cumulative percentage of subjects with maintenance of serum testosterone <= 50 ng/dL from Day 29 to Day 85. Started Jan 2020; status: completed.
02
Drugs
Baituowei
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04563936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563936.